Prokidney (PROK) Invested Capital (2021 - 2022)
Prokidney (PROK) posted quarterly Invested Capital of $80687.0 for Q2 2022, up 214.66% year-over-year from $25643.0 in Q2 2021, and up 84.96% quarter-over-quarter from $43623.0 in Q1 2022.
Prokidney (PROK) Invested Capital (2021 - 2022) Analysis & Trends
Prokidney (PROK) has reported Invested Capital for 2 consecutive years, with $80687.0 the latest figure, recorded in Q2 2022.
- In Q2 2022, Invested Capital rose 214.66% year-over-year to $80687.0; the TTM figure through Mar 2023 stood at $80687.0 (down 31.3% YoY), while the FY2021 annual figure was $10000.0, changed N/A from the prior year.
- Invested Capital rose to $80687.0 in Q2 2022 per PROK's latest filing, from $43623.0 in the prior quarter.
- Across five years, Invested Capital topped out at $80687.0 in Q2 2022 and bottomed at $10000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 190.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 380.00 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Prokidney | 679.95 Mn | 679.95 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 80,687.00 |
| Mar 31, 2022 | 43,623.00 |
| Dec 31, 2021 | 10,000.00 |
| Sep 30, 2021 | 38,178.00 |
| Jun 30, 2021 | 25,643.00 |